Clinical Trial Update: Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating nelfinavir as a drug to sensitize bortezomib in patients with myeloma not responding to proteasome inhibitors; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• Nelfinavir (nelfinavir)

Snippet

Sponsor: Swiss Cancer Institute | Conditions: Myeloma | Phase 2 | Status: COMPLETED